S

Superluminal Medicines

ML-driven design of candidate small molecules

Vice President, Head of Legal

Full-TimePosted on 10/15/2026
$315k - $357k/yr+ Bonus + Equity
Expert
JD
Boston, MA, USA
In Person
LegalLegal Counsel & Legal Support

About the job

Requirements
  • A Juris Doctor (J.D.) degree from an accredited law school.
  • An active license to practice law and membership in good standing of at least one U.S. state bar or the District of Columbia.
  • 10–15+ years of relevant legal experience, with significant experience supporting life sciences, biotechnology, or pharmaceutical companies.
  • Experience with in-house legal leadership, ideally within a growth-stage life sciences company.
  • Experience across corporate, commercial, and general legal matters, with the ability to serve as a strategic legal partner to the business.
  • Experience with corporate governance, commercial transactions, securities, and other strategic legal matters.
  • Experience advising CEOs, CFOs, executive teams, and Boards of Directors.
  • Experience managing outside counsel and establishing or scaling legal processes and infrastructure.
  • Experience supporting significant corporate milestones, financings, strategic transactions, and evolving governance requirements.
  • Experience working with external legal and business advisors on complex corporate transactions and strategic matters.
  • Experience with intellectual property, licensing, collaborations, and research-related agreements in a life sciences environment.
Responsibilities
  • Serve as a senior legal advisor to the CEO, executive leadership team, and Board of Directors.
  • Lead corporate governance matters, including Board and committee support, corporate records, resolutions, minutes, and governance policies.
  • Establish and maintain effective governance practices and processes as the company grows.
  • Advise on corporate structure, capitalization, equity matters, securities, and other corporate matters in partnership with Finance and external advisors.
  • Support significant corporate milestones, financings, strategic initiatives, and other corporate transactions.
  • Partner with Finance and executive leadership on legal considerations related to material events, corporate communications, and disclosures.
  • Monitor developments in applicable laws and regulations and advise leadership on their implications for the company as the business evolves.
  • Advise the business on a broad range of commercial, operational, and other legal matters.
  • Provide legal leadership and support for negotiation of material commercial agreements, including strategic collaborations, licensing arrangements, research agreements, and other significant contracts, in partnership with the Contract Management function and relevant business stakeholders.
  • Provide legal guidance on contract terms, risk allocation, negotiation strategy, and approval of material agreements.
  • Partner with Business Development, Operations, Finance, and other functions to provide practical legal guidance that enables the business while appropriately managing risk.
  • Develop legal templates, playbooks, and guidance that enable the organization to address recurring legal matters efficiently.
  • Partner with Contract Management to establish appropriate escalation points and ensure legal review of material or higher-risk agreements.
  • Partner closely with scientific, clinical, and business development teams on intellectual property and related legal matters.
  • Partner with Clinical, Regulatory, and other scientific teams on legal matters associated with the transition to clinical development, research activities, vendors, investigators, collaborations, and other development activities.
  • Work with external intellectual property counsel to protect and manage the company’s intellectual property portfolio.
  • Support licensing, collaboration, partnering, and other transactions involving intellectual property and scientific assets.
  • Advise on confidentiality, data ownership, publications, research collaborations, and related matters.
  • Partner with internal teams and external counsel to identify and appropriately manage legal risks related to the company’s intellectual property and scientific assets.
  • Establish the company’s legal operating model, including determining which capabilities should be managed internally versus through external counsel.
  • Develop a roadmap for expanding the legal function as the company’s needs evolve.
  • Establish scalable processes for corporate records, Board materials, legal entity management, legal spend, and outside counsel management.
  • Develop legal policies, processes, templates, and approval authorities appropriate for the company’s size and complexity.
  • Select, manage, and develop external legal partners.
  • Establish appropriate legal technology and knowledge-management infrastructure.
  • Build an internal legal team over time as business needs warrant.
  • Partner with the Head of HR and executive leadership on employment-related legal matters.
  • Provide guidance on employment agreements, executive arrangements, employee relations, workforce changes, policies, and other employment matters.
  • Partner with external employment counsel as appropriate.
  • Help ensure employment practices and policies evolve appropriately as the organization grows.
  • Develop and evolve appropriate legal and compliance policies and processes as the company’s business and regulatory activities evolve.
  • Partner with internal functions and external advisors, including Clinical, Regulatory, and Quality resources, on legal and regulatory risk management.
  • Develop and maintain appropriate policies, training, and controls as the company scales.
  • Advise leadership on securities law, insider trading, materiality, disclosure, and other legal considerations relevant to corporate communications and transactions.
  • Partner with Finance and other functions on disclosure, document retention, and related legal and internal control processes.
  • Identify emerging legal and compliance risks and provide practical recommendations to the executive team.
  • Support insurance, risk management, and other corporate risk matters in partnership with Finance and Operations.
  • Lead or support legal work associated with financings, strategic partnerships, licensing transactions, acquisitions, divestitures, and other significant corporate transactions.
  • Lead or support legal diligence processes and coordinate internal stakeholders and external advisors.
  • Manage relationships with outside counsel and other legal advisors supporting significant transactions and strategic initiatives.
  • Provide clear, commercially oriented recommendations to senior leadership on transaction structure, legal risk, and execution.
  • Support complex and time-sensitive strategic initiatives, balancing legal and business considerations.
Desired Qualifications
  • Experience navigating complex securities, disclosure, and corporate governance matters in a private or public company environment is strongly preferred.

About the company

S

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series B

Total Funding

$213M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 Series B raised $60 million from BVF, Deep Track, Perceptive.
  • Management expects Phase 1 obesity data after year-end 2026, creating a near-term catalyst.
  • Lilly's $1.3 billion collaboration expands optionality beyond one program into cardiometabolic obesity.

What critics are saying

  • Rhythm's Imcivree already treats rare obesity, forcing Superluminal to beat an approved drug.
  • If Phase 1 misses safety or efficacy, the platform loses its first clinical proof point.
  • If Lilly program underperforms, the $1.3 billion deal and future financing weaken.

What makes Superluminal Medicines unique

  • Superluminal couples Cryo-EM, ML, and GPCR biophysics to design candidate-ready small molecules.
  • Its lead MC4R agonist is selective, biased, and entering Phase 1 by year-end 2026.
  • Eli Lilly partnered in August 2025, validating Superluminal's GPCR platform for cardiometabolic targets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Flexible Work Hours
  • Hybrid Work Options
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

38%

1 year growth

38%

2 year growth

38%
BioCentury
Sep 4th, 2026
Superluminal's $60M series B to drive first clinical study: Finance Report.

Superluminal's $60M series B to drive first clinical study: Finance Report. Plus: Gene insertion company Typewriter launches with series A; Electra files for NASDAQ listing; and more. By Paul Bonanos, Director of Biopharma Intelligence, and Lindsay Martin, Biopharma Analyst September 4, 2026 6:07 PM PDT During a quiet week ahead of the U.S. holiday, Superluminal announced a $60 million series B round intended to support its first candidate's entry into the clinic. A crossover syndicate led by BVF Partners backed Superluminal Medicines Inc. in the round, with Deep Track Capital and Perceptive Advisors joining as new investors. Series A and seed round leader RA Capital Management also participated, among other previous investors... Your competitors are already reading this Don't make your next decision without this analysis. Trusted by biotech, pharma, and investment leaders to move first on trial data, financings, and regulatory shifts. Benchmark any deal against $2.25T in tracked biopharma transactions 25,000+ deals, 4,600+ discontinued products, 1,300+ milestones, and more Spot emerging targets before they hit industry pipelines Query BioCentury directly inside the AI tools you already use See What's Behind a BioCentury Subscription Full access to this article, BCIQ data, AI Connectors, and everything BioCentury publishes. Need just this one Article text only: no BCIQ data, AI Connectors, deal comparables, or coverage as the story develops.

Pharma Journalist
Sep 4th, 2026
Superluminal Medicines raises $60 million to advance GPCR drug pipeline.

Superluminal Medicines raises $60 million to advance GPCR drug pipeline. On Sep 4, 2026 Superluminal Medicines has raised $60 million in an oversubscribed Series B financing to advance its drug development programs, including a lead treatment for rare genetic forms of obesity and hypothalamic obesity. The biotechnology company plans to use the funding to move its lead program toward clinical development, with a Phase 1 trial expected to begin by the end of 2026. The company will also use the funds to expand its pipeline of small-molecule therapies targeting G protein-coupled receptors (GPCRs) for endocrine and cardiometabolic diseases. BVF Partners, L.P. led the financing. New investors Deep Track Capital and Perceptive Advisors joined existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Superluminal's lead program is a selective, biased MC4R agonist being developed for rare genetic forms of obesity and hypothalamic obesity. The MC4R pathway plays an important role in regulating appetite and energy balance and has been linked to conditions including Bardet-Biedl syndrome (BBS) and hypothalamic obesity. The company believes its approach could improve treatment activity while reducing unwanted side effects by selectively activating the signaling pathways linked to the desired therapeutic effect. In preclinical studies, the candidate showed high selectivity and a favorable safety profile. Beyond these rare obesity indications, Superluminal sees potential for its MC4R program in other metabolic diseases. Future applications could include Prader-Willi syndrome and combination treatment with GLP-1 therapies for broader patient populations. "This financing represents an important milestone in Superluminal's evolution as we transition from a discovery platform company to a clinical-stage biotechnology company," said Cony D'Cruz, CEO of Superluminal Medicines. He added that the funding will allow the company to advance its first clinical program while continuing to develop new GPCR-targeted medicines. Superluminal has built its drug discovery platform around artificial intelligence and machine learning, protein dynamics, structural biology, and GPCR-focused drug design. Its technology combines Cryo-EM capabilities with machine learning models, small-molecule design, predictive ADME and toxicology tools, and GPCR biophysics. The platform is designed to help researchers identify and develop small-molecule drug candidates against GPCRs, a large class of drug targets that can be difficult to study because of their structural and functional complexity. The company is also continuing collaborations with pharmaceutical companies. This includes a partnership with Eli Lilly to develop small-molecule therapies targeting undisclosed GPCRs for cardiometabolic diseases and obesity. Harsha Paladugu, Investment Analyst at BVF and a member of Superluminal's Board of Directors, said the company's MC4R program could address an important unmet need for patients with rare forms of obesity. He also highlighted the potential of Superluminal's discovery platform to produce new medicines against challenging GPCR targets. With the new financing, Superluminal is moving closer to becoming a clinical-stage biotechnology company while expanding its focus on GPCR drug discovery and next-generation treatments for obesity and cardiometabolic diseases.

Pharmaceutical Technology
Sep 4th, 2026
Superluminal Medicines secures $60m to advance rare obesity therapy.

Superluminal Medicines secures $60m to advance rare obesity therapy. Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026. US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and Company, Gaingels, Insight Partners, Nvidia, and RA Capital Management. The company plans to use the proceeds to progress its lead candidate, a selective, biased melanocortin-4 receptor (MC4R) agonist, towards a Phase I clinical trial by the end of this year. The additional funds will support the expansion of other pipeline programmes and the development of small-molecule, GPCR-targeted therapies for endocrine and cardiometabolic diseases. Superluminal's MC4R agonist is being developed for rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity. The MC4R pathway plays a key role in energy homeostasis and appetite regulation, which has been established in these rare diseases. According to the company, activating only the signalling pathways responsible for the desired effect may maximise therapeutic activity and minimise unwanted side effects. In preclinical models, the therapy demonstrated high selectivity and a favourable safety profile. Superluminal has also suggested possible future applications in conditions such as Prader-Willi syndrome, and potential utility in broader populations in combination with GLP-1 therapies. Superluminal Medicines CEO Cony D'Cruz said: "This financing represents an important milestone in Superluminal's evolution as Pharmaceutical Technology transition from a discovery platform company to a clinical-stage biotechnology company. "Rare genetic forms of obesity and hypothalamic obesity are devastating diseases with limited treatment options, and Pharmaceutical Technology believe its selective, biased MC4R agonist has the potential to make a meaningful difference for these patients. "With the support of this exceptional investor syndicate, we are positioned to advance our first clinical programme while continuing to build a pipeline of GPCR-targeted medicines for patients with significant unmet needs in cardiometabolic diseases and obesity." The company's research and development efforts focus on integrating advanced structural biology with proprietary machine learning tools. Superluminal further maintains collaborations with pharmaceutical partners, including an existing partnership with Eli Lilly and Company, to develop small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity. Give your business an edge with its leading industry insights.

PR Newswire
Sep 3rd, 2026
Superluminal Medicines raises $60M Series B to advance rare obesity drug into Phase 1 trial

Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, with participation from Deep Track Capital and Perceptive Advisors alongside existing investors including RA Capital Management, Insight Partners, and NVIDIA. The Boston-based biotechnology company will use the proceeds to advance its lead programme — a selective MC4R agonist for rare genetic forms of obesity and hypothalamic obesity — into a Phase 1 clinical trial by the end of 2026. The funding will also support expansion of its GPCR-focused discovery platform. Superluminal integrates AI, machine learning, and structural biology to develop small-molecule therapies targeting G protein-coupled receptors for endocrine and cardiometabolic diseases. The company maintains a strategic collaboration with Eli Lilly for advancing GPCR-targeted therapeutics.

The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.